Unknown

Dataset Information

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.


ABSTRACT:

Background

In vitro data and early clinical results suggest that metformin has desirable antineoplastic effects and has a theoretical benefit on castration-resistant prostate cancer (CRPC).

Objective

To determine whether the use of metformin would be associated with improved clinical outcomes and a reduction in the development of CRPC.

Design, setting, and participants

Data from 2901 consecutive patients (157 metformin, 162 diabetic non-metformin, and 2582 nondiabetic) with localized prostate cancer treated with external-beam radiation therapy from 1992 to 2008 were collected from a single institution in the United States.

Intervention

Use of metformin in localized prostate cancer.

Outcome measurements and statistical analysis

Univariate and multivariate

SUBMITTER: Spratt DE 

PROVIDER: S-EPMC4034673 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature